Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established.
ABSTRACT
Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established.
In this study, associations between 19 BRCA1 and 33 BRCA2 missense substitution variants and breast cancer risk were investigated through a breast cancer case control study using genotyping data from 38 studies of predominantly European ancestry (41,890 cases and 41,607 controls) and nine studies of Asian ancestry (6, 
INTRODUCTION
Mutation screening of the BRCA1 and BRCA2 genes has resulted in the discovery of thousands of unique germline BRCA1 and BRCA2 variants. Many pathogenic variants of BRCA1 or BRCA2 resulting in truncation of these proteins, along with a small number of pathogenic missense variants, have been associated with high risks of breast cancer with cumulative risks of 55% to 85% by age 70 (1) . In contrast, the influence on cancer risk of many rare variants of uncertain significance (VUS), accounting for between 2% and 10% of results from genetic testing, is not known (2-4). As a result, carriers of VUS in these predisposition genes cannot benefit from cancer risk management strategies for women with pathogenic mutations.
Clinical classification of BRCA1 and BRCA2 VUS has been largely based on probability-based models which incorporate likelihood-ratios associated with family history of cancer, cosegregation of variants with breast and ovarian cancer within families, tumor histopathology, and prior probabilities of pathogenicity associated with cross-species amino acid sequence conservation (5, 6) . While over 200 BRCA1 and BRCA2 variants have been classified as pathogenic or neutral/non-pathogenic using a multifactorial likelihood model (7-10) , many VUS remain because of limited availability of families segregating the variants. Clinical classification of VUS in BRCA1 and BRCA2 has been further complicated by the identification of variants with partial effects on protein function (5, 11, 12) . However, to date only the BRCA1 c.5096G>A, p.Arg1699Gln (R1699Q) variant has been associated with a reduced cumulative risk of breast cancer (24% by age 70) (13) . R1699Q has also been associated with lower penetrance relative to the pathogenic c.5095C>T, p.Arg1699Trp (R1699W) variant in the same residue. In this study, the influence of 52 missense variants in BRCA1 and BRCA2 on breast cancer risk was investigated using the iCOGS breast cancer case-control project (14) . In addition, the impact of the BRCA2 c.9104A>C, p.Tyr3035Ser (Y3035S), c.7522G>A, p.Gly2508Ser (G2508S), and c.8187G>T, p.Lys2729Asn (K2729N) variants on BRCA2 function were evaluated relative to known pathogenic and neutral variants using biochemical, cell-based homology directed repair (HDR), and in vivo embryonic stem (ES) cell-based assays. The combination of these genetic and functional studies show that missense variants in the DNA binding domain of BRCA2 with partial effects on protein function can confer moderate risks of breast cancer.
MATERIALS AND METHODS

Participants
Breast cancer cases and controls from 38 studies of predominantly European ancestry (41,890 cases with invasive disease and 41,607 controls) and nine studies of Asian ancestry (6, 269 cases and 6,624 controls) from the Breast Cancer Association Consortium (BCAC) were used for genotyping (Supplementary Table S1 ). All studies were approved by local ethics committees and institutional review boards. 
Genotyping
Genotyping was conducted using the custom Illumina Infinium array (iCOGS) (14) . DNA samples containing each of the variants were included in iCOGS genotyping as positive controls and were used to inform genotype calling. Genotypes were called with the GenCall algorithm.
Descriptions of sample and genotype quality control have been published (14, 16) . Cluster plots for rare variants for this study were manually evaluated relative to positive control samples. 
Statistical Methods
Case-control analysis -The association of each variant with breast cancer risk was assessed using unconditional logistic regression, adjusting for study (categorical). Analyses were restricted to either Caucasian or Asian women. Cases selected for iCOGS based on personal or family history of breast cancer were excluded to obtain unbiased OR estimates for the general population. The significance of associations (P-values) was determined by the likelihood ratio test comparing models with and without carrier status as a covariate. Because this study was focused on estimating breast cancer risk associated with each variant, analyses were not adjusted for multiple testing. Moderate risk of breast cancer was defined as odds ratio (OR) from 2.0 to 5.0 and high risk of breast cancer was defined as OR>5.0.
Segregation analysis -Risks of breast cancer were assessed using pedigrees based on the likelihood of the observed pedigree genotypes conditional on the pedigree phenotypes and the genotype of the index case. The primary analysis calculated the penetrance for breast cancer in carriers of the p.Y3035S variant assuming a constant relative risk with age. A second analysis allowed for a similar pattern of age specific effects as for population based pathogenic BRCA2 variants and calculated the optimal cumulative penetrance at 75% of pathogenic BRCA2 variants. The age-specific hazard ratio (HR), by decade, was assumed to be a constant multiple of the population based estimates for BRCA2 pathogenic mutations, with cumulative penetrance re-estimated at each trial value of the multiplier. This provided for a similar pattern of agespecific effects as in BRCA2, but allowed testing of different penetrance values and only required estimation of a single parameter. Models were fitted under maximum likelihood theory using a modified version of the LINKAGE genetic analysis package (17) . Non-carriers were assumed to be at population risks with incidence rates taken from cancer registry data obtained from Cancer Incidence in Five Continents, VIII (IARC, Lyon) and risk ratios (RR, the age specific Reported breast cancers with unknown age at diagnosis were excluded from all analyses.
Cancers other than breast (including ovarian cancer) were treated as unaffected at the age of their cancer diagnosis.
Cell Lines V-C8 cells were a kind gift from Dr. M.Z. Zdzienicka. 293T cells were obtained from ATCC (CRL-3216). Cells were authenticated by short tandem repeat analysis using the kit GenePrint10 kit (Promega). All the cell lines used in this study were routinely checked for mycoplasma contamination using the MycoProbe Mycoplasma Detection Set (R&D Systems).
Cells were limited to 6 weeks in culture.
Homology directed repair (HDR) assay
The HDR assay for evaluating the influence of variants in the BRCA2 DNA binding domain (DBD) on BRCA2 homologous recombination DNA repair activity has been described previously (11) . Full-length human BRCA2 wild-type and mutant cDNA expression constructs were co- phCMV1 expression plasmids and purified as described (18, 19) . Briefly, 10 x 15-cm plates of HEK293 cells were transiently transfected using TurboFect (Thermo Scientific) following the manufacturer specifications and harvested 30 hours post-transfection. Cell extracts were bound to Amylose resin (NEB), and the protein was eluted with 10 mM maltose. The eluate was further purified by ion exchange using BioRex 70 resin (BIO-RAD) and step eluted at 250mM, 450 mM, and 1M NaCl (18, 19) . Each fraction was tested for nuclease contamination. The 1M NaCl fractions were used for the DNA binding assay because they were free of nuclease contamination. 
ES cell functional assays
After Cre-recombinase transfection, mBrca2 depleted cells were selected for restoration of the HPRT minigene using hypoxanthine-aminopterin-thymidine (HAT) containing medium. HAT resistant clones were pooled and evaluated for BRCA2 activity using functional assays. In the mES cell HDR assay, cells were transfected with an I-Sce1 expression vector, pCMV-REDISce, and GFP positive cells were quantified by flow cytometry 48 hr after transfection. mES cells were also treated with varying doses of PARP inhibitor (KU-0058948, Astra Zeneca) and viable cells were quantified after 48 hr. Cell survival was calculated as the fraction of treated surviving mES cells relative to the cell count of untreated surviving cells per cell line. Table S2 ). Among these, 18 are located in the DNA binding domain (amino acids 2460-3170).
RESULTS
Association of
The BRCA1 R1443X truncating pathogenic variant was associated with high risk of breast cancer (odds ratio (OR) = 8.3, p=0.045) in the Caucasian case-control analysis in iCOGS (Table   1 and Supplementary Table S3) , consistent with what has been estimated for truncating pathogenic BRCA1 variants. Among the missense variants, c.5096G>A, p.Arg1699Gln (R1699Q) was associated with a moderate risk of breast cancer (OR=4.29, p=0.009) ( Table 1 and Supplementary Table S3 ). This result was lower than expected for pathogenic BRCA1
variants, but consistent with the moderate penetrance of this variant estimated from familybased studies (13 To assess further the association with breast cancer for the BRCA2 G2508S and Y3035S potentially clinically relevant moderate risk variants, pedigrees for segregation analysis were collected through the ENIGMA consortium. Nineteen pedigrees with the Y3035S variant were collected (Fig. 1, Supplementary Fig. S1, Supplementary Table S4 ). Only one pedigree was Table S4) . A second analysis, allowing for a similar pattern of age specific effects as for population-based pathogenic BRCA2 truncating variants, estimated the optimal cumulative penetrance for Y3035S at 0.75 of known pathogenic truncating BRCA2 variants, and yielded a similar risk ratio for breast cancer (Supplementary Table S4 ). Y3035S co-occurred with a pathogenic BRCA2 variant (S1882X) in Pedigree G (Supplementary Fig. S1 ). Co-occurrence with S1298del in 
Pedigree K (Figure 1) was not informative because S1298del is a VUS. Together the casecontrol study and the pedigree analysis suggest that Y3035S is associated with moderately increased breast cancer risk.
Cell-based HDR analysis of BRCA2 variants Inactivation or depletion of BRCA2 has been associated with deficient homology directed repair (HDR) of DNA double strand breaks (23) , which can be quantified with a cell-based HDR green fluorescent protein (GFP) reporter assay (24) . This assay has shown 100% sensitivity and specificity for known pathogenic missense variants in the BRCA2 DNA-binding domain and has been used for characterization of BRCA2 VUS (8, 11, 25) . In this study, the impact of the G2508S, A2717S, K2729N, and Y3035S missense variants on BRCA2 HDR activity was assessed relative to the D2723H and R3052W known pathogenic and the c.9292T>C
p.Tyr3098His (Y3098H) known neutral BRCA2 variants (11, 26) . D1420Y was not evaluated because the variant is not located in the BRCA2 DBD. All wildtype and mutant BRCA2 proteins displayed equivalent levels of expression relative to β-actin by western blot (Supplementary Fig.   S2 ). The D2723H and R3052W Class 5 pathogenic variants (11) showed substantial loss of BRCA2 HDR activity ( Fig. 2A and Table 2 ). In contrast, BRCA2 Y3035S showed intermediate levels (2.3-fold relative to D2723H) ( Fig. 2A and Table 2 ). While reduced relative to wildtype activity, this level of HDR activity was associated with >99% probability of neutrality. Similarly, BRCA2 K2729N showed reduced HDR activity relative to the wildtype protein ( Fig. 2A and Table 2 ), which was consistent with a mild influence on breast cancer risk (OR=1.41, p=0.004) in the Asian population, and >99% probability of neutrality ( Fig. 2A) . Together these results show that the HDR assay is calibrated relative to levels of cancer risk, with minor functional effects for variants associated with low-or modest risks of breast cancer such as c.9976A>T, p.Lys3326Ter (K3326X) (OR=1.28) (27) and K2729N (OR=1.41), more substantial functional effects for the intermediate risk Y3035S (OR=2.52), and strong effects for known pathogenic variants such as D2723H and R3052W ( Fig. 2A) . Thus, the HDR assay may predict the level of risk associated with any BRCA2 DBD variant.
Single strand DNA (ssDNA) binding activity of BRCA2 variants BRCA2 directly binds to ssDNA and recruits RAD51 to ssDNA at sites of DNA damage during homologous recombination DNA repair (18, 28) . Hence, ssDNA binding is integral to the homologous recombination activity of BRCA2. On this basis, an in vitro biochemical assay was used to examine the influence of the BRCA2 variants on BRCA2 ssDNA binding activity. Fulllength wildtype and mutant human BRCA2 proteins tagged with (N-terminal) green fluorescence protein (GFP) and maltose-binding protein (MBP) (GFP-MBP-BRCA2) were expressed and purified to near homogeneity ( Supplementary Fig. S3 ) as described previously (18, 19) . Fulllength BRCA2 protein expression was confirmed by western blotting using an antibody against the C-terminus of BRCA2 (Supplementary Fig. S3 ). The ssDNA binding activity of full-length wildtype and mutant BRCA2 proteins was evaluated using an electrophoretic mobility shift assay (EMSA). The wildtype protein bound to ssDNA with a yield of ~18% at the maximum attainable concentration of BRCA2 protein (Fig. 2B, 2C , and complex formation (~8%) (Fig. 2B, 2C , and Table 2 ). Likewise, the Y3035S variant exhibited 2-fold reduced complex formation compared to the wildtype protein (Fig. 2B, 2C , and Table 2 ). In contrast, G2508S, A2717S, and K2729N showed only partially reduced (~12% to 13%) proteinssDNA complex formation (Fig. 2B, 2C , and Table 2 ). These findings are consistent with predictions from the crystal structure of the BRCA2 DBD, where Y3035S is predicted to impair DNA binding, similarly to R3052W, because of proximity to DNA in the ssDNA-BRCA2 complex ( Supplementary Fig. S4 ) (26) . Overall, the results suggest that the reduction in HDR activity observed for Y3035S ( Fig. 2A ) is due to a defective ssDNA binding activity. deficiency. HDR activity of surviving cells was assessed using the DR-GFP reporter assay. BRCA2 W31C showed only 14% (p<0.001) activity, whereas BRCA2 Y3035S, G2508S, and K2729N variants displayed 50% (p=0.002), 55% (p=0.007), and 70% (p=0.02) of wildtype HDR activity, respectively (Fig. 3A and Table 2 ). In contrast, HDR activity in cells expressing A2717S
was not significantly different to wildtype protein (Fig. 3A and Table 2 ). The sensitivity of wildtype and mutant BRCA2 expressing ES cells to PARP inhibitor (KU-0058948) was evaluated to determine whether the reduction in HDR associated with some of the variants was sufficient to confer sensitivity to PARP inhibitor. Sensitivity was evaluated by counting viable cells after 48 hours of exposure to different doses of drug. Wildtype BRCA2, G2508S, and A2717S did not show sensitivity to PARP inhibitor, whereas W31C expressing cells showed significant sensitivity (Fig. 3B and Table 2 ). K2729N and Y3035S resulted in partial rescue of ES cell sensitivity (Fig. 3B and Table 2 ). Collectively, the ES cell HDR activity of the variants showed high concordance with the ORs from the case-control study, with Y3035S displaying partially deficient BRCA2 activity. In contrast, the level of HDR activity did not correlate well with different levels of PARP inhibitor sensitivity, although Y3035S was partially sensitive to PARP inhibitor, consistent with the results from other assays.
DISCUSSION
In this study, associations between 52 BRCA1 and BRCA2 missense variants and breast cancer risk were evaluated using a large breast cancer case-control study. To our knowledge, this is the largest case-control study conducted to establish the clinical relevance and estimate the risks of individual rare BRCA1 and BRCA2 variants encoding missense substitutions. The case-control analysis showed that BRCA1 c.5096G>A, R1699Q (OR=4.29) and BRCA2 c.9104A>C, Y3035S (OR=2.52) were associated with moderately increased breast cancer risks for Caucasian women (Table 1) , whereas BRCA2 c.7522G>A, G2508S (OR=2.68) and c.8187G>T, K2729N (OR=1.41) were associated with increased risks for Asian women. This is CAN-16-2568 the first study to estimate low to moderate risks of breast cancer for specific BRCA1 and BRCA2 missense variants.
The moderate risk of breast cancer associated with the BRCA1 R1699Q variant (OR=4.29) was consistent with previous findings from segregation analyses of breast cancer families, which estimated that R1699Q was associated with a cumulative risk of breast or ovarian cancer by age 70 years of 24% relative to the pathogenic R1699W variant and BRCA1 truncating variants (13) . Similarly the quantitative ENIGMA multifactorial likelihood prediction model based on family data and sequence conservation yielded a posterior probability of pathogenicity for R1699Q of only 0.79 (13) . Consistent with these findings, BRCA1 R1699Q protein has shown only partial protein function in HDR and other in vitro experiments (12, 13) . Thus, the casecontrol study and functional studies are consistent in identifying R1699Q as a moderate risk variant in BRCA1.
BRCA2 Y3035S was associated with increased risk of disease (OR=2.52) for Caucasian women. While the numbers of cases and controls with the Y3035S variant were small, the moderate risk estimate is supported by family data showing partial co-segregation with breast cancer, and one pedigree in which BRCA2 Y3035S co-occurred with BRCA2 c.5645C>A p.Ser1882Ter (S1882X) (Supplementary Fig. S1 ). Several sequence-based in silico prediction models including MetaLR, MetaSVM, Vest3, and A-GVGD (prior probability of pathogenicity of 0.66) (Supplemental Table S2 ) predicted Y3035S as deleterious. In addition, the missense substitution is predicted as likely deleterious by a protein likelihood ratio model based on sequence analysis (31) . Analyses of splicing defects using Minigene-based assays have shown no influence on RNA splicing (32) , suggesting that the increased risks are not due to abnormal splicing. Importantly, functional analysis of Y3035S using multiple independent assays consistently revealed partial activity. Y3035S showed intermediate BRCA2 HDR activity in VC8 CAN-16-2568 cells, failed to restore HDR activity in ES cells (Fig. 3A) , and only partially rescued sensitivity to PARP inhibition in ES cells (Fig. 3B) . Similarly, Y3035S showed significantly reduced ssDNA complex formation (Fig. 2B and 2C ) consistent with the location of Y3035 in the crystal structure of the BRCA2 DBD (28) (Supplementary Fig. S4 ). Together the functional studies indicate that Y3035S is a hypomorphic BRCA2 variant. Overall the case-control association study and functional analyses provide the first evidence that a hypomorphic BRCA2 missense variant can confer a moderate risk of breast cancer. However, Y3035S is consistently reported as "likely benign" and "benign" in the ClinVar public database. Since this database is widely used by researchers and clinicians, this under-appreciation of moderate risks of breast cancer associated with this variant has the potential to impact patient care. Further prospective studies are required to estimate age-dependent risks of cancer and to inform management protocols for carriers of this and other hypomorphic BRCA2 variants.
The BRCA2 G2508S (OR=2.68, p=0.004) variant was associated with a moderate risk of breast cancer in Asian women, but could not be evaluated in the Caucasian population ( Table 1 ). The variant was predicted neutral by a protein likelihood prediction model (31) , but was predicted deleterious by other in silico prediction models including MetaLR, MetaSVM, Vest3, and A-GVGD (prior probability of pathogenicity of 0.66) ( Supplementary Table S2 ). However, the HDR V-C8 cell-based assay showed only mildly reduced activity similar to K2729N (OR=1.41) and p.K3326X (OR=1.28) (27) , which are both classified as neutral ( Fig. 2A) . Likewise, the impact of G2508S on ssDNA binding was limited and most similar to K2729N (Fig. 2B, 2C ). Although G2508S only partially rescued HDR activity in ES cells (Fig. 3A) , the variant completely rescued sensitivity to PARP inhibition in ES cells similar to wildtype BRCA2 (Fig. 3B) . Thus, the functional results suggest a limited impact on BRCA2 activity. As the variant has only been detected in the East Asian population (33, 34) , one possibility is that genetic and environmental Author Manuscript Published OnlineFirst on March 10, 2017; DOI: 10.1158/0008-5472. CAN-16-2568 risk and the discrepancy between the case-control and functional study results. Further studies are needed to resolve this issue, but for now the breast cancer risks associated with this variant must be treated with caution. BRCA2 K2729N (OR=1.41, p=0.004) is also common in Asians, but rare in Caucasians (34) . This variant has previously been classified as neutral by the multifactorial likelihood classification model (8) . Consistent with these findings, functional analysis of K2729N showed only a minor influence on HDR function (8, 11) (Fig. 2A ) and ssDNA binding (Fig. 2B) , and substantial rescue of ES cell-based HR (Fig. 3A) and ES cell drug sensitivity (Fig. 3B) . The mild defect in HR function correlated well with the low risk of breast cancer (OR=1.41, P=0.004) associated with the K2729N variant in the Asian case-control study.
This study contains the first evidence that a biochemical assay using purified full-length BRCA2 protein can be used to assess the DNA binding capacity of missense variants in the BRCA2 DBD. While purification of wildtype full-length BRCA2 protein to near homogeneity has previously been described (18, 19) , in this study the functional integrity of purified mutant BRCA2 proteins was assessed for the first time in a quantitative ssDNA binding assay. Fulllength proteins were used to limit potentially inaccurate interpretation of effects from partial protein fragments. The correlation of the ssDNA binding assay and HDR activity and the structural inspection of the DNA binding domain suggest that the reduction in HDR activity may result from a defect in ssDNA binding. The study also showed that the influence of BRCA2 variants on HDR activity does not fully predict the response to PARP inhibitor in ES cells ( Fig.   3A and 3B ). These findings suggest that only large reductions in HDR activity (<50%) will result in PARP inhibitor sensitivity. Whether tumors associated with these missense variants are sensitive to PARP inhibitor remains to be determined. Importantly, HDR results for variants with low or moderate levels of risk [K3326X (OR=1.28) (27) , K2729N (OR=1.41), Y3035S (OR=2.52)], suggest that the HDR assay can be calibrated to differentiate between variants with high, moderate, or low breast cancer risks (Fig. 2A) .
Additional studies that combine the HDR assay data with family-based and sequence based models may result in classification of certain BRCA2 VUS as moderate breast cancer risk missense variants. ES cell complementation assays have also been used to identify inactivating missense variants in the BRCA2 DBD (14, 20, 29, 35) , although the assay needs to be validated relative to known pathogenic and neutral BRCA2 variants before the results can be incorporated into VUS classification models.
In summary, this study establishes for the first time the existence of BRCA2 missense variants that are associated with moderate risks of breast cancer. Only through the very large iCOGS case-control association study was it possible to define the BRCA2 missense variant (Y3035S) as a moderate risk pathogenic variant for breast cancer (OR=2.52, p=0.038). Functional studies showed consistent partial or hypomorphic activity associated with Y3035S, suggesting that other BRCA2 variants with partial protein activity should be evaluated for moderate risks of breast cancer. Given that the age-related and lifetime risks of breast and ovarian cancer associated with moderate risk variants are likely to be substantially lower than for known pathogenic missense and truncating BRCA2 variants, risk management guidelines for individuals with these mutations may need to be redefined. Because Y3035S appears to confer similar risks of breast cancer as CHEK2 or ATM inactivating mutations, perhaps individuals carrying Y3035S or other moderate risk BRCA2 variants may benefit from following 
